RNA-bind proteins (RBPs) are typical types of proteins that bind RNA to play critical roles in the development of cancer. Recent proteome-wide studies have identified RBPs and an increasing number of studies have revealed the dysregulation of RBPs in various types of cancer, such as mutation, copy number variation, and RBP expression perturbation at the protein or gene level.
During the development and the progression of cancer, various mechanisms contribute to the aberrant dysregulation of RBP, such as genetic alteration, epigenetic change, noncoding RNA-medicated regulation, and post-translational modifications. With the progress of high throughput sequencing technology, some recent studies have highlighted precise dysregulated RBPs in specific cancers, however, their implications across cancer types remain unknown.
In addition, although some targets of RBPs were identified based on computational or experimental methods, the genome-wide RBP-gene regulatory network is largely unknown and little is known about the synergetic interaction between RBPs and other regulators in cancer. We still have a lack of knowledge of how these networks were perturbed in cancer.
The aim of this Research Topic is therefore to reveal the roles of RBPs in cancer, which will provide novel insights into the development and progression of various cancer types. We will accept Review, Original Research, Research Reports or specific comments on recently published articles that are related to RBPs in cancer.
RNA-bind proteins (RBPs) are typical types of proteins that bind RNA to play critical roles in the development of cancer. Recent proteome-wide studies have identified RBPs and an increasing number of studies have revealed the dysregulation of RBPs in various types of cancer, such as mutation, copy number variation, and RBP expression perturbation at the protein or gene level.
During the development and the progression of cancer, various mechanisms contribute to the aberrant dysregulation of RBP, such as genetic alteration, epigenetic change, noncoding RNA-medicated regulation, and post-translational modifications. With the progress of high throughput sequencing technology, some recent studies have highlighted precise dysregulated RBPs in specific cancers, however, their implications across cancer types remain unknown.
In addition, although some targets of RBPs were identified based on computational or experimental methods, the genome-wide RBP-gene regulatory network is largely unknown and little is known about the synergetic interaction between RBPs and other regulators in cancer. We still have a lack of knowledge of how these networks were perturbed in cancer.
The aim of this Research Topic is therefore to reveal the roles of RBPs in cancer, which will provide novel insights into the development and progression of various cancer types. We will accept Review, Original Research, Research Reports or specific comments on recently published articles that are related to RBPs in cancer.
